Guidance for the Development of Vaginal Contraceptive Drugs (NDA)

us-fda-guidance-73ca77a9f8c9469282dc06a570c7d83eGuidance for the Development of Vaginal Contraceptive Drugs (NDA)Guidance

Abrir fonte

Administrative guidance, not enacted legislation. This captured publisher edition preserves the listed document and attachments; later developments are not independently consolidated.

Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

The FDA published Good Guidance Practices in February 1997. This guidance was developed and issued prior to that date.

Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.











Continue sua pesquisa no ChatGPT ou Claude
Conecte o Omnilex para pesquisar o corpus jurídico pelo seu assistente de IA.